Lv568
1100 积分 2024-04-28 加入
The present and future of bispecific antibodies for cancer therapy
13天前
已完结
Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?
17天前
已完结
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
1个月前
已完结
Core Modifications of GSK3335103 toward Orally Bioavailable αvβ6 Inhibitors with Improved Synthetic Tractability
1个月前
已完结
Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474
1个月前
已完结
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
1个月前
已完结
Dual 5-HT2A and 5-HT2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis
1个月前
已完结
Potent, Selective Agonists for the Cannabinoid-like Orphan G Protein-Coupled Receptor GPR18: A Promising Drug Target for Cancer and Immunity
1个月前
已完结
The relaxin receptor RXFP1 signals through a mechanism of autoinhibition
1个月前
已完结
Structural and Physicochemical Features of Oral PROTACs
1个月前
已完结
皖公网安备34019202002308
